242 related articles for article (PubMed ID: 33571962)
1. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
[TBL] [Abstract][Full Text] [Related]
2. The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis.
Dranka-Bojarowska D; Lekstan A; Olakowski M; Jablonska B; Lewinski A; Musialski P; Sobczyk W; Kapalka A; Lampe P
J Physiol Pharmacol; 2015 Oct; 66(5):653-63. PubMed ID: 26579571
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
Mroczko B; Lukaszewicz-Zajac M; Wereszczynska-Siemiatkowska U; Groblewska M; Gryko M; Kedra B; Jurkowska G; Szmitkowski M
Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
[TBL] [Abstract][Full Text] [Related]
4. Concentrations and activities of metalloproteinases 2 and 9 and their inhibitors (TIMPS) in chronic pancreatitis and pancreatic adenocarcinoma.
Lekstan A; Lampe P; Lewin-Kowalik J; Olakowski M; Jablonska B; Labuzek K; Jedrzejowska-Szypulka H; Olakowska E; Gorka D; Filip I; Dranka-Bojarowska D
J Physiol Pharmacol; 2012 Dec; 63(6):589-99. PubMed ID: 23388475
[TBL] [Abstract][Full Text] [Related]
5. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.
Kuwatani M; Kawakami H; Kubota Y; Kawakubo K; Ito YM; Togo S; Ikeda T; Kusama K; Kobayashi Y; Murata T; Sakamoto N
Pancreatology; 2019 Jun; 19(4):569-577. PubMed ID: 31031206
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis.
Mroczko B; Groblewska M; Gryko M; Kedra B; Szmitkowski M
J Clin Lab Anal; 2010; 24(4):256-61. PubMed ID: 20626020
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
[TBL] [Abstract][Full Text] [Related]
9. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
[TBL] [Abstract][Full Text] [Related]
10. [Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) values in patients with pancreatic cancer or pancreatitis].
Changchine CS; Yung CY; Tzen KY
Changgeng Yi Xue Za Zhi; 1991 Mar; 14(1):32-8. PubMed ID: 2039968
[TBL] [Abstract][Full Text] [Related]
11. TNM staging for GIT cancers is correlated with the level of MMPs and TGF-β1.
El-Ashmawy NE; Khedr NF; Mansour MG; Al-Ashmawy GM
Clin Exp Med; 2020 Nov; 20(4):545-555. PubMed ID: 32772210
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor 2 (TIMP-2) in pancreatic cancer (PC).
Łukaszewicz-Zając M; Gryko M; Pączek S; Szmitkowski M; Kędra B; Mroczko B
Oncotarget; 2019 Jan; 10(3):395-403. PubMed ID: 30719232
[TBL] [Abstract][Full Text] [Related]
13. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
14. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
Joergensen MT; Brünner N; De Muckadell OB
Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
[TBL] [Abstract][Full Text] [Related]
15. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes.
Pezzilli R; Calculli L; Melzi d'Eril G; Barassi A
Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):553-557. PubMed ID: 27733327
[TBL] [Abstract][Full Text] [Related]
16. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
[TBL] [Abstract][Full Text] [Related]
17. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer.
Kaur S; Chakraborty S; Baine MJ; Mallya K; Smith LM; Sasson A; Brand R; Guha S; Jain M; Wittel U; Singh SK; Batra SK
PLoS One; 2013; 8(2):e55171. PubMed ID: 23383312
[TBL] [Abstract][Full Text] [Related]
18. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
19. The usefulness of serial changes in serum CA19-9 levels in the diagnosis of pancreatic cancer.
Tanaka N; Okada S; Ueno H; Okusaka T; Ikeda M
Pancreas; 2000 May; 20(4):378-81. PubMed ID: 10824692
[TBL] [Abstract][Full Text] [Related]
20. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]